Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2013, Article ID 791397, 6 pages
http://dx.doi.org/10.1155/2013/791397
Clinical Study

Prospective Single-Site Experience with Radiofrequency-Targeted Vertebral Augmentation for Osteoporotic Vertebral Compression Fracture

1Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
2DFINE, Inc., 3047 Orchard Parkway, San Jose, CA 95134, USA
3Miller Scientific Consulting, Inc., 26 Portobello Road, Arden, NC 28704, USA
4The Jon Block Group, 2210 Jackson Street, Suite 401, San Francisco, CA 94115, USA

Received 25 April 2013; Revised 5 September 2013; Accepted 15 September 2013

Academic Editor: Heikki Kroger

Copyright © 2013 Franklin G. Moser et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Vertebral augmentation procedures are widely used to treat osteoporotic vertebral compression fractures (VCFs). We report our initial experience with radiofrequency-targeted vertebral augmentation (RF-TVA) in 20 patients aged 50 to 90 years with single-level, symptomatic osteoporotic VCF between T10 and L5, back pain severity > 4 on a 0 to 10 scale, Oswestry Disability Index ≥ 21%, 20% to 90% vertebral height loss compared to adjacent vertebral body, and fracture age < 6 months. After treatment, patients were followed through hospital discharge and returned for visits after 1 week, 1 month, and 3 months. Back pain severity improved 66% ( ), from 7.9 (95% CI: 7.1 to 8.6) at pretreatment to 2.7 (95% CI: 1.5 to 4.0) at 3 months. Back function improved 46% ( ), from 74 (95% CI: 69% to 79%) at pretreatment to 40 (95% CI: 33% to 47%) at 3 months. The percentage of patients regularly consuming pain medication was 70% at pretreatment and only 21% at 3 months. No adverse events related to the device or procedure were reported. RF-TVA reduces back pain severity, improves back function, and reduces pain medication requirements with no observed complications in patients with osteoporotic VCF.